Stock AFX CARL ZEISS MEDITEC AG
Add to a list
To use this feature you must be a member
Log inSign up

Financials Carl Zeiss Meditec AG

Equities

AFX

DE0005313704

Advanced Medical Equipment & Technology

Market Closed - Xetra
Other stock markets
 11:35:08 2024-04-26 EDT 		5-day change 1st Jan Change
100.3 EUR +1.31% Intraday chart for Carl Zeiss Meditec AG +2.66% +1.48%
04-24 CARL ZEISS MEDITEC AG : Gets a Buy rating from UBS ZD
04-23 CARL ZEISS MEDITEC AG : Receives a Sell rating from JP Morgan ZD

Valuation

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 9,355 9,660 14,852 9,610 7,407 8,971 - -
Enterprise Value (EV) 1 8,678 8,952 14,016 8,823 6,683 8,051 8,610 8,434
P/E ratio 58.4 x 78.8 x 62.9 x 32.7 x 25.5 x 34.3 x 27.1 x 23.6 x
Yield 0.62% 0.46% 0.54% 1.02% 1.33% 1.06% 1.22% 1.39%
Capitalization / Revenue 6.41 x 7.23 x 9.02 x 5.05 x 3.55 x 3.96 x 3.52 x 3.23 x
EV / Revenue 5.95 x 6.7 x 8.51 x 4.64 x 3.2 x 3.55 x 3.37 x 3.04 x
EV / EBITDA 27.3 x 37.6 x 32.2 x 18.9 x 15.8 x 17.7 x 15.1 x 12.9 x
EV / FCF 36.7 x 67 x 42.1 x 60.7 x 48.8 x 25.8 x 31.7 x 26.1 x
FCF Yield 2.73% 1.49% 2.37% 1.65% 2.05% 3.88% 3.15% 3.83%
Price to Book 6.69 x 6.75 x 8.95 x 4.77 x 3.43 x 3.84 x 3.57 x 3.24 x
Nbr of stocks (in thousands) 89,441 89,441 89,441 89,441 89,441 89,441 - -
Reference price 2 104.6 108.0 166.0 107.4 82.82 100.3 100.3 100.3
Announcement Date 19-12-06 20-12-12 21-12-10 22-12-09 23-12-12 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,459 1,335 1,647 1,903 2,089 2,267 2,551 2,778
EBITDA 1 318.1 238 435.2 466.6 422.2 454.9 569.1 654.9
EBIT 1 235 177.6 373.6 396.9 348.1 364.8 471.9 545.5
Operating Margin 16.1% 13.3% 22.69% 20.86% 16.66% 16.09% 18.5% 19.64%
Earnings before Tax (EBT) 1 229.9 178.7 339 403.5 412.6 367.7 457.3 527.9
Net income 1 159.8 122.4 236.3 293.9 290.4 257.6 325.5 373.7
Net margin 10.95% 9.16% 14.35% 15.45% 13.9% 11.36% 12.76% 13.45%
EPS 2 1.790 1.370 2.640 3.290 3.250 2.922 3.703 4.243
Free Cash Flow 1 236.6 133.5 332.5 145.4 137 312.3 271.3 322.9
FCF margin 16.21% 10% 20.19% 7.64% 6.56% 13.77% 10.63% 11.63%
FCF Conversion (EBITDA) 74.37% 56.11% 76.41% 31.16% 32.45% 68.66% 47.67% 49.31%
FCF Conversion (Net income) 148.1% 109.12% 140.74% 49.47% 47.18% 121.23% 83.35% 86.42%
Dividend per Share 2 0.6500 0.5000 0.9000 1.100 1.100 1.065 1.228 1.390
Announcement Date 19-12-06 20-12-12 21-12-10 22-12-09 23-12-12 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: September 2020 S1 2021 S1 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4 2024 S2 2025 Q1 2025 Q2
Net sales 1 714.9 767.4 410.2 445.2 855.4 477.5 569.9 470.3 504.2 974.5 535.1 579.7 475 502.5 1,010 613.1 701.5 1,345 - -
EBITDA 1 - - - - - - - - 101.9 - - - - 69.03 158 137.7 198.5 330 - -
EBIT 1 105.3 162.7 - 102.9 177.3 98.58 121 63.1 83.62 - 101 103.2 46 54.64 106 118.7 152.3 278 - -
Operating Margin 14.73% 21.2% - 23.11% 20.73% 20.64% 21.23% 13.42% 16.58% - 18.88% 17.81% 9.68% 10.87% 10.5% 19.36% 21.71% 20.67% - -
Earnings before Tax (EBT) 1 96.1 - - 120.1 - 88.33 141 - 90.71 - 132.3 116.5 54.7 54.65 - 120.7 153.8 - - -
Net income 1 - - - 90.73 - 62.53 102.7 - 62 - 92.15 85.2 37.4 38.26 - 83.92 110.1 - - -
Net margin - - - 20.38% - 13.1% 18.02% - 12.3% - 17.22% 14.7% 7.87% 7.61% - 13.69% 15.7% - - -
EPS 2 - 1.120 0.4200 1.020 - 0.7000 1.150 0.5700 0.6900 - 1.030 0.9600 0.4200 0.4276 - 0.9396 1.222 - - -
Dividend per Share 2 - - - - - - 1.100 - - - - 1.100 - - - - 1.027 - - -
Announcement Date 20-05-11 21-05-28 22-02-11 22-05-13 22-05-13 22-08-05 22-12-09 23-02-14 23-05-15 23-05-15 23-08-06 23-12-12 24-02-14 - - - - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 678 707 835 787 725 920 361 537
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 237 134 333 145 137 312 271 323
ROE (net income / shareholders' equity) 11.9% 8.65% 15.3% 16% 13.4% 11.4% 13.1% 13.9%
ROA (Net income/ Total Assets) 8.67% 6.07% 10.7% 11.3% 9.92% 7.65% 8.33% 8.96%
Assets 1 1,842 2,016 2,205 2,609 2,928 3,368 3,908 4,168
Book Value Per Share 2 15.60 16.00 18.60 22.50 24.10 26.10 28.10 31.00
Cash Flow per Share 2 2.460 2.000 4.050 2.100 2.800 3.370 4.010 4.660
Capex 1 20.3 45 30.1 82 114 93.6 105 114
Capex / Sales 1.39% 3.37% 1.83% 4.31% 5.45% 4.13% 4.13% 4.11%
Announcement Date 19-12-06 20-12-12 21-12-10 22-12-09 23-12-12 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Carl Zeiss Meditec AG

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
14
Last Close Price
100.3 EUR
Average target price
108.7 EUR
Spread / Average Target
+8.34%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

1st Jan change Capi.
CARL ZEISS MEDITEC AG Stock Carl Zeiss Meditec AG
+1.48% 9.58B
THERMO FISHER SCIENTIFIC Stock Thermo Fisher Scientific
+8.07% 219B
DANAHER CORPORATION Stock Danaher Corporation
+6.59% 183B
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+11.26% 133B
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+26.57% 108B
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+13.35% 52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
-0.62% 48.2B
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-0.93% 40.37B
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+11.54% 39.35B
RESMED, INC. Stock ResMed, Inc.
+26.76% 32.03B
Other Advanced Medical Equipment & Technology
  1. Stock Market
  2. Equities
  3. AFX Stock
  4. Financials Carl Zeiss Meditec AG